ReviewCureus2026
Systematic Review of Neuropsychiatric Side Effects Induced by Mefloquine: Evidence From Case Reports and Clinical Studies.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mefloquine is an effective antimalarial drug widely used for malaria treatment and chemoprophylaxis. However, its use has been associated with a range of neuropsychiatric adverse effects, ranging from mild sleep disturbances to severe psychiatric reactions. The aim of this study is to systematically review the available evidence on neuropsychiatric adverse effects associated with mefloquine use and to characterize their clinical spectrum, time to onset, and reported outcomes. A systematic literature search was conducted to identify studies reporting neuropsychiatric adverse effects associated with mefloquine. Studies meeting the predefined eligibility criteria were included, and relevant clinical and adverse effect data were extracted. The methodological quality of included studies was assessed using the National Institutes of Health (NIH) Study Quality Assessment Tools. Of 207 records identified, 25 studies were included after removing duplicates and applying the eligibility criteria. These comprised 17 case reports and 8 clinical studies. The case reports described 19 patients aged 7-63 years with a wide range of neuropsychiatric manifestations. Frequently reported adverse effects included hallucinations, depression, anxiety, and insomnia, while psychosis, confusion, and mania were also reported. Other manifestations included paranoia, delusions, restlessness, nightmares, depersonalization/derealization, suicidal ideation, and delirium. The time to onset ranged from a few hours to several months after exposure. Clinical studies demonstrated variable frequencies of neuropsychiatric adverse effects across different populations and study designs. Mefloquine is associated with a broad spectrum of neuropsychiatric adverse effects, ranging from mild symptoms such as anxiety and insomnia to severe psychiatric manifestations. Early recognition and careful patient selection are important when prescribing mefloquine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.